Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV

Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine authority, Zabdeno ® (Ad26.ZEBOV) and Mvabea ® (MVA-BN-Filo), was well permitted and convinced a robust vulnerable response in both healthy grown-ups and grown-ups living with HIV. These findings, alongside Phase 3 data lately published in The Lancet Infectious Conditions, support the implicit precautionary use of the vaccine authority to cover people at threat of acquiring Ebola. The authority was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from the World Health Organization (WHO) in April 2021.
The data is from the Phase 2 EBL2002 study, which was conducted in Burkina Faso, Cote d’Ivoire, Kenya and Uganda and enrolled 668 healthy grown-ups and 142 grown-ups living with HIV. There were no safety signals of concern.

“ These data add to the growing body of substantiation supporting the precautionary use of the Johnson & Johnson Ebola vaccine authority to cover people at threat of Ebola. This is critical to our vision of guarding some of the world’s most vulnerable and underserved people – including people living with HIV – by precluding Ebola outbreaks before they start,” said Paul Stoffels,M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson. “ The recentre-emergence of Ebola in the Democratic Republic of the Congo, which is the rearmost in a series of outbreaks in Africa in just the once time, support the need for a visionary approach to address this patient public health trouble.”
Further than 30 outbreaks have been declared since the Ebola contagion was discovered in 1976, the worst of which have passed in Africa in the once seven times. Johnson & Johnson accelerated the development of its Ebola vaccine at the onset of the 2014-2016 Ebola extremity, which caused further than deaths.

The Company has responded to recent Ebola outbreaks by making available vaccine rules to governments and the World Health Organization (WHO). Most lately in May 2021, Johnson & Johnson blazoned it would make available over to Ebola vaccine rules in support of a WHO beforehand pierce clinical program launched in response to an outbreak in Guinea and aimed at precluding Ebola in West Africa. In addition to aiding with outbreak response, the Company is concentrated on sweats to insure its Ebola vaccine authority is more astronomically accessible to the countries and communities in Africa who need it most.
Learn Further about our work on Ebola and our broader commitment to outwit epidemic pitfalls.

About Johnson & Johnson’s Ebola Vaccine
The Johnson & Johnson Ebola vaccine authority was developed in collaboration with Bavarian Nordic A/ S, and is manufactured using Janssen’s personal AdVac ® viral vector technology. The AdVac ® vaccine platform is also used for the Company’s COVID-19 vaccine. To date, further than people have entered at least the first cure of the Ebola vaccine, including further than who have been completely vaccinated with both boluses.

Johnson & Johnson’s Ebola vaccine authority originates from a cooperative exploration program with the NIH and entered direct backing and preclinical services from the National Institute of Allergy and Infectious Conditions, part of NIH, under Contract Number HHSN272200800056C. Farther backing for the Ebola vaccine authority has been handed in part with civil finances from the Office of the Assistant Secretary for Preparedness and Response, BARDA under Contract Figures HHSO100201700013C and HHSO100201500008C.

The Innovative Medicines Initiative (IMI) handed backing through the IMI Ebola Programme to support a number of colleges that initiated multiple clinical trials and other vaccine development conditioning. The colleges funded by the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking are EBOVAC1 ( entitlement nr. 115854), EBOVAC2 ( entitlement nr. 115861), EBOVAC3 ( entitlement nr. 800176), EBOMAN ( entitlement nr. 115850) and EBODAC ( entitlement nr. 115847). This Joint Undertaking receives support from the EU’s Horizon 2020 Framework Programme for Research and Innovation and the European Federation of Pharmaceutical Diligence and Associations (EFPIA).

Johnson & Johnson also acknowledges its numerous strategic mates in the ongoing global clinical program for the vaccine authority, including Bavarian Nordic A/ S, Centre Muraz, Coalition for Epidemic Preparedness Inventions (CEPI), College of Medicine and Allied Health Lores (COMAHS, University of Sierra Leone), Democratic Republic of the Congo Ministry of Public Health, Republic of Rwanda Ministry of Health and Rwanda Biomedical Center, Emory University’s Project San Francisco (Kigali)/ Center for Family Health Research, Emory University, Epicentre, Grameen Foundation, Inserm, Inserm Transfert, Institut National de Recherce Biomédicale (INRB), London School of Hygiene & Tropical Medicine (LSHTM), Médecins Sans Frontières (MSF), Rinda Ubuzima, Sierra Leone Ministry of Health and Sanitation, Uganda Virus Research Institute (UVRI), Université de Kinshasa (UNIKIN), University of Antwerp, University of Oxford, Walter Reed Army Institute of Research (WRAIR), World Health Organization, World Vision Ireland, Wellcome Trust, Vibalogics, and all the people who have shared in the Ebola vaccine clinical trials.

Source link: https://www.jnj.com/